01—Abstract
Summary
Summary of the 10-K filed February 23, 2012. Cited figures are marked; the original filing is the authoritative source.
DexCom, Inc., in its 2011 10-K filing, reported significant revenue growth driven by its SEVEN PLUS continuous glucose monitoring system.
The company is focused on expanding its product offerings and market reach, including development of in-hospital solutions and partnerships for insulin pump integration. Despite strong revenue increases, DexCom continued to incur net losses, underscoring the high R&D and SG&A expenses associated with its growth strategy and the medical device market.
Key investor considerations include the company's progress in gaining market acceptance for continuous glucose monitoring, the importance of reimbursement from third-party payors, and the ongoing legal dispute with Abbott Diabetes Care. DexCom's future success hinges on its ability to navigate regulatory pathways, secure broader reimbursement, manage manufacturing scale-up, and continue product innovation in a competitive landscape.
02—Key points
Key Highlights
- Product revenue increased significantly, reaching $65.9 million in 2011 compared to $40.2 million in 2010, primarily due to increased sales volume of the SEVEN PLUS system.
- The company reported a net loss of $44.7 million for 2011, reflecting substantial investments in research and development and selling, general, and administrative expenses.
- DexCom is actively pursuing product development and partnerships, including integrating its technology into insulin pumps from Animas, Insulet, Roche, and Tandem, and developing an in-hospital glucose monitoring system (GlucoClear).
- Reimbursement remains a critical factor for widespread adoption, with the company actively working with seven major private third-party payors for coverage policies, though Medicare coverage is still pending.
- A significant risk factor highlighted is the ongoing patent infringement litigation with Abbott Diabetes Care, which could materially impact the company's ability to sell its key products.
- The company is also focused on expanding its sales and marketing infrastructure, including a direct sales force and distribution partnerships, to drive market penetration.
- DexCom experienced an FDA warning letter in February 2010 regarding sensor wire fractures and labeling, but reported to have taken corrective actions and received notification of adequate remediation by November 2010.
03—One dollar
Follow one dollar
For each $1.00 of revenue in FY2011, Dexcom Inc lost $0.59.
- Revenue$76.3M100.0%
- Cost of revenue−$40.4M52.9%
- Gross profit$35.9M47.1%
- Operating costs−$80.7M105.8%
- Operating income−$44.8M58.7%
- Interest, other & tax$100,0000.1%
- Net income−$44.7M58.6%
04—Financials
Financial Highlights
Figures from 10-KFY2011filed February 23, 2012Financial Statements
FY2011 against FY2010
| Line item | FY2011FY2010 | Change |
|---|---|---|
| Revenue | $76.30M$48.60M | +57.0% |
| Cost of Revenue | $40.40M$30.20M | +33.8% |
| Gross Profit | $35.90M$18.40M | +95.1% |
| R&D Expenses | $29.60M$23.20M | +27.6% |
| SG&A Expenses | $51.10M$40.50M | +26.2% |
| Operating Expenses | $80.70M$63.70M | +26.7% |
| Operating Income | -$44.80M-$45.30M | +1.1% |
| Interest Expense | $0$1.50M | −100.0% |
| Net Income | -$44.70M-$55.20M | +19.0% |
| EPS (Basic) | $-0.17$-0.24 | +29.9% |
| Shares Outstanding (Basic) | 262.40M227.60M | +15.3% |
05—Questions
Frequently Asked Questions
What is DexCom's primary product and how is it performing?
DexCom's primary product is the SEVEN PLUS continuous glucose monitoring (CGM) system for ambulatory use by people with diabetes. The company reported significant revenue growth for this product in 2011, with product revenue increasing by approximately 64% year-over-year, indicating growing market adoption.
What are the main financial challenges facing DexCom?
Despite revenue growth, DexCom continues to incur significant net losses. In 2011, the net loss was $44.7 million. This is driven by high research and development (R&D) and selling, general, and administrative (SG&A) expenses, which are necessary for product development, clinical trials, regulatory approvals, and market expansion in the competitive medical device industry.
How is DexCom addressing reimbursement and market access?
Reimbursement from third-party payors is crucial for DexCom's product adoption. The company has actively engaged with seven major private payors to establish coverage policies for CGM devices. However, Medicare coverage is still pending. Patients not covered by these policies bear the full cost, which can limit widespread use. DexCom is employing in-house expertise and a field-based team to secure and liberalize these coverage policies.
What are the key risks and legal issues highlighted in the filing?
A major risk is the ongoing patent infringement lawsuit filed by Abbott Diabetes Care. This litigation could potentially force DexCom to cease selling its SEVEN PLUS and GlucoClear products if an unfavorable outcome occurs. Additionally, the company faces risks related to regulatory approvals, manufacturing scale-up, reliance on single-source suppliers, and the potential for product liability claims.
06—Continue